These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 8113721)
41. Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. el-Sawy IH; Mohamed ON East Mediterr Health J; 1999 Sep; 5(5):922-32. PubMed ID: 10983531 [TBL] [Abstract][Full Text] [Related]
42. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Zheng X; Weinberger KM; Gehrke R; Isogawa M; Hilken G; Kemper T; Xu Y; Yang D; Jilg W; Roggendorf M; Lu M Virology; 2004 Nov; 329(2):454-64. PubMed ID: 15518823 [TBL] [Abstract][Full Text] [Related]
43. Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study. Attanasio R; Lanford RE; Dilley D; Stunz GW; Notvall L; Henderson AB; Kennedy RC Biologicals; 1991 Oct; 19(4):347-53. PubMed ID: 1797045 [TBL] [Abstract][Full Text] [Related]
44. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Tacket CO; Losonsky G; Lubeck MD; Davis AR; Mizutani S; Horwith G; Hung P; Edelman R; Levine MM Vaccine; 1992; 10(10):673-6. PubMed ID: 1523878 [TBL] [Abstract][Full Text] [Related]
45. Construction and characterization of adenovirus co-expressing hepatitis B virus surface antigen and interleukin-6. Lindley T; Virk KP; Ronchetti-Blume M; Goldberg K; Lee SG; Eichberg JW; Hung PP; Cheng SM Gene; 1994 Jan; 138(1-2):165-70. PubMed ID: 8125296 [TBL] [Abstract][Full Text] [Related]
46. Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. Levrero M; Barban V; Manteca S; Ballay A; Balsamo C; Avantaggiati ML; Natoli G; Skellekens H; Tiollais P; Perricaudet M Gene; 1991 May; 101(2):195-202. PubMed ID: 1829048 [TBL] [Abstract][Full Text] [Related]
47. Properties of recombinant hepatitis B vaccine. Ohmura T; Ohmizu A; Sumi A; Ohtani W; Uemura Y; Arimura H; Nishida M; Kohama Y; Okabe M; Mimura T Biochem Biophys Res Commun; 1987 Dec; 149(3):1172-8. PubMed ID: 2962578 [TBL] [Abstract][Full Text] [Related]
48. [The prospects for using the genetically engineered surface antigen of the hepatitis B virus (HBsAg) expressed by recombinant poxvirus strains as the basis for vaccines against hepatitis B]. Zheleznova NV; Mukomolov SL; Zhebrun AB; Noskov FS; Malkova II; Shargorodskaia EP; Al'tshteĭn AD; Pliutnikova VA; Lavrent'eva IN; Ptichnikova NN Zh Mikrobiol Epidemiol Immunobiol; 1996; (5):49-53. PubMed ID: 9082729 [TBL] [Abstract][Full Text] [Related]
49. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. Singh M; Cattaneo R; Billeter MA J Virol; 1999 Jun; 73(6):4823-8. PubMed ID: 10233943 [TBL] [Abstract][Full Text] [Related]
50. The immunogenicity of recombinant LC16mO vaccinia virus harboring HBsAg gene in mice. Watanabe K; Morita M; Sato T; Yausi K; Kojima A Biologicals; 1991 Apr; 19(2):77-85. PubMed ID: 1888498 [TBL] [Abstract][Full Text] [Related]
51. Helper independent recombinant adenovirus vectors: expression of HIV env or HBV surface antigen. Chanda PK; Natuk RJ; Dheer SK; Lubeck MD; Bhat BM; Mason BB; Greenberg L; Mizutani S; Davis AR; Hung PP Int Rev Immunol; 1990; 7(1):67-77. PubMed ID: 2132880 [No Abstract] [Full Text] [Related]
52. Antibody responses in mice stimulated by various doses of the potato-derived major surface antigen of hepatitis B virus. Youm JW; Won YS; Jeon JH; Moon KB; Kim HC; Shin KS; Joung H; Kim HS Clin Vaccine Immunol; 2010 Dec; 17(12):2029-32. PubMed ID: 20943879 [TBL] [Abstract][Full Text] [Related]
53. Host cell protein testing strategy for hepatitis B antigen in Hexavalent vaccine - Towards a general testing strategy for recombinant vaccines. Toinon A; Fontaine C; Thion L; Gajewska B; Carpick B; Nougarede N; Uhlrich S Biologicals; 2018 Jul; 54():1-7. PubMed ID: 29861269 [TBL] [Abstract][Full Text] [Related]
54. Immunogenicity of hybrid hepatitis B surface antigen particles. Mancini M; Schlienger K; Tiollais P; Michel ML Int Rev Immunol; 1994; 11(2):143-51. PubMed ID: 8046275 [TBL] [Abstract][Full Text] [Related]
55. Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Chengalvala MV; Bhat RA; Bhat BM; Vernon SK; Lubeck MD Vaccine; 1999 Mar; 17(9-10):1035-41. PubMed ID: 10195612 [TBL] [Abstract][Full Text] [Related]
56. Antibody responses to recombinant hepatitis B vaccines. Hessel L; West DJ Vaccine; 2002 May; 20(17-18):2164-5. PubMed ID: 12009268 [No Abstract] [Full Text] [Related]
57. Immunogenicity of recombinant vaccinia viruses expressing hepatitis B virus surface antigen in mice. Grigorieva IM; Grigoriev VG; Zakharova LG; Pashvykina GV; Shevlyagin VY; Altstein AD Immunol Lett; 1993 Jun; 36(3):267-71. PubMed ID: 8370598 [TBL] [Abstract][Full Text] [Related]
58. Antibodies to hepatitis B surface antigen (HBsAg) elicited by immunization with a synthetic peptide covalently linked to liposomes. Neurath AR; Kent SB; Strick N J Gen Virol; 1984 May; 65 ( Pt 5)():1009-14. PubMed ID: 6202827 [TBL] [Abstract][Full Text] [Related]
59. Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen. Watanabe K; Kobayashi H; Kajiyama K; Morita M; Yasuda A; Gotoh H; Saeki S; Sugimoto M; Saito H; Kojima A Vaccine; 1989 Feb; 7(1):53-9. PubMed ID: 2718607 [TBL] [Abstract][Full Text] [Related]